Huilai Zhang
机构：Tianjin Medical University · ORCID：0000-0002-8558-3131
发表论文 368 篇 · 总被引 5425 次 · h-index 37
代表论文
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial (2025 · Journal of Clinical Oncology · 被引 22)
- Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group Database (2025 · International Journal of Radiation Oncology*Biology*Physics · 被引 4)
- Epidemiology of mature T-cell and NK-cell neoplasms: east and west (2025 · The Lancet Regional Health - Western Pacific · 被引 4)
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups (2025 · Blood · 被引 3)
- Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO (2025 · Blood · 被引 3)
- PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study (2025 · Blood · 被引 3)